-
公开(公告)号：EP3444237B1
公开(公告)日：2020-10-28
申请号：EP17769433.8
申请日：2017-03-22
申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： ZHU, Li , YANG, Yanqing , DAI, Liguang , DUAN, Xiaowei , YANG, Zhao , ZHANG, Hui , HU, Yuandong , PENG, Yong , HAN, Yongxin , ZHAO, Rui , TIAN, Xin , WANG, Shanchun
IPC分类号： C07D203/24 , A61K31/396 , A61P35/00
-
12.发明授权
公开(公告)号：EP3412674B1
公开(公告)日：2020-09-16
申请号：EP17747007.7
申请日：2017-02-04
发明人： DING, Zhaozhong , SUN, Fei , HU, Yinghu , ZHOU, Yilong , WANG, Zheng , ZHAO, Rui , YANG, Ling
IPC分类号： C07D487/04 , A61K31/519 , A61P31/12
-
公开(公告)号：EP3330264B1
公开(公告)日：2020-05-06
申请号：EP16829879.2
申请日：2016-07-29
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： GONG, Feng , LI, Xinlu , ZHAO, Rui , ZHANG, Xiquan , XU, Xinhe , LIU, Xijie , XIAO, Dengming , HAN, Yongxin
IPC分类号： C07D401/14 , A61K31/496 , A61P35/00
-
公开(公告)号：EP3434671A1
公开(公告)日：2019-01-30
申请号：EP17769434.6
申请日：2017-03-22
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： ZHU, Li , DUAN, Xiaowei , DAI, Liguang , YANG, Zhao , YANG, Yanqing , ZHANG, Hui , HU, Yuandong , PENG, Yong , HAN, Yongxin , ZHAO, Rui , TIAN, Xin , WANG, Shanchun
IPC分类号： C07D275/02 , A61K31/425 , A61K31/433 , A61P35/00
摘要： Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers.
-
公开(公告)号：EP3412673A1
公开(公告)日：2018-12-12
申请号：EP17747006.9
申请日：2017-02-04
发明人： DING, Zhaozhong , SUN, Fei , HU, Yinghu , ZHOU, Yilong , ZHAO, Rui , YANG, Ling
IPC分类号： C07D487/04
CPC分类号： C07D487/04
摘要： The present invention relates to a method for preparing a pyrrolo[3,2-d]pyrimidine compound (the compound represented by formula I), and corresponding intermediates.
-
公开(公告)号：EP3412672A1
公开(公告)日：2018-12-12
申请号：EP17747004.4
申请日：2017-02-04
发明人： DING, Zhaozhong , SUN, Fei , HU, Yinghu , ZHOU, Yilong , WANG, Zheng , ZHAO, Rui , YANG, Ling
IPC分类号： C07D487/04 , A61K31/519 , A61P31/12
摘要： The present invention relates to crystalline form A of a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)-benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (formula I), a method for preparing the crystalline form A, and the use thereof.
-
公开(公告)号：EP3330264A1
公开(公告)日：2018-06-06
申请号：EP16829879.2
申请日：2016-07-29
申请人： Chia Tai Tianqing Pharmaceutical Group Co.,Ltd , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： GONG, Feng , LI, Xinlu , ZHAO, Rui , ZHANG, Xiquan , XU, Xinhe , LIU, Xijie , XIAO, Dengming , HAN, Yongxin
IPC分类号： C07D401/14 , A61K31/496 , A61P35/00
摘要： The present invention discloses a crystal of citrate salt of pyridine-substituted 2-aminopyridine-based protein kinase inhibitors, in particular, to crystal of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4'-methoxy-6'-((S)-2-methylpiperazin -1-yl)-3,3'-bipyridin-6-amine citrate salt, a method for preparation thereof, a crystalline composition and a pharmaceutical composition comprising the crystal, and further discloses the use of crystals of citrate salt of the compound of Formula I in protein kinase-related diseases. The crystals of citrate salt according to the present invention are superior to 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4'-methoxy-6'-((S)-2-methylpiperazin-1-yl)-3,3'-bipyridin-6-amine or other salts of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4'-methoxy-6'-((S)-2-methylpiperazin-1-yl)-3,3'-bipyridin-6-amine in at least one aspect of bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, and the like.
-
公开(公告)号：EP3412672B1
公开(公告)日：2020-07-15
申请号：EP17747004.4
申请日：2017-02-04
发明人： DING, Zhaozhong , SUN, Fei , HU, Yinghu , ZHOU, Yilong , WANG, Zheng , ZHAO, Rui , YANG, Ling
IPC分类号： C07D487/04 , A61K31/519 , A61P31/12
-
公开(公告)号：EP3434671B1
公开(公告)日：2020-10-21
申请号：EP17769434.6
申请日：2017-03-22
申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus BioPharma Co., Ltd.
发明人： ZHU, Li , DUAN, Xiaowei , DAI, Liguang , YANG, Zhao , YANG, Yanqing , ZHANG, Hui , HU, Yuandong , PENG, Yong , HAN, Yongxin , ZHAO, Rui , TIAN, Xin , WANG, Shanchun
IPC分类号： A61K31/425 , A61K31/433 , A61P35/00 , C07D275/03 , C07D285/10 , A61P35/02
-
20.发明公开
公开(公告)号：EP3412674A1
公开(公告)日：2018-12-12
申请号：EP17747007.7
申请日：2017-02-04
发明人： DING, Zhaozhong , SUN, Fei , HU, Yinghu , ZHOU, Yilong , WANG, Zheng , ZHAO, Rui , YANG, Ling
IPC分类号： C07D487/04 , A61K31/519 , A61P31/12
摘要： The present invention relates to a trifluoroacetate salt of a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (formula I), crystalline form B of the trifluoroacetate salt, methods for preparing the trifluoroacetate salt and crystalline form B, and uses of the trifluoroacetate salt and crystalline form B.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.022 秒)
